<p><em>旗艦與 GSK 框架合作下的首次可行性協議</em></p>
<p><em>協議將利用 ProFound 和 Quotient 的平台技術來發現和驗證呼吸系統和肝臟疾病的新治療方法</em></p>
<p>, /PRNewswire/ -- 旗艦開創（Flagship Pioneering）是一家致力於變革性平台和產品的科學創新引擎，今天宣佈 ProFound Therapeutics 和 Quotient Therapeutics 已與 GSK 簽署了單獨的可行性協議，以發現和驗證呼吸系統和肝臟疾病的新靶點和治療方法。這是旗艦與 GSK 框架合作下籤署的首個以公司為中心的協議，旨在將 GSK 的疾病領域專業知識和開發能力與旗艦的生物平台公司生態系統相結合，包括其新穎的模式和技術。</p>
<p>&#34;旗艦開創與 GSK 有着共同的使命，通過將創新的新技術與深厚的藥物開發專業知識相結合，加速為最需要幫助的患者開發突破性藥物，&#34;旗艦開創的管理合夥人 Paul Biondi 表示。&#34;這些協議將兩種開創性的方法結合在一起，以推進呼吸系統和肝臟疾病的創新治療，並識別可能改變疾病進程的新穎和差異化的靶點。&#34;</p>
<p><strong>利用擴展的人類蛋白組推進呼吸系統疾病的新藥物</strong></p>
<p>ProFound 將利用其 ProFoundry™平台，該平台結合了最先進的蛋白質檢測技術、針對性的高通量功能驗證方法和先進的計算工具，從擴展的人類蛋白組中挖掘出豐富的差異化潛在蛋白藥物和藥物靶點，這是一組由人類基因組編碼的先前未被識別的蛋白質。通過兩項單獨的協議，ProFound 將推進基礎發現，以表徵與慢性阻塞性肺病（COPD）和特發性肺纖維化（IPF）強相關的新蛋白，並檢查它們在這些疾病中的治療相關性。</p>
<p><strong>利用體細胞基因組學解鎖呼吸系統和肝臟疾病的新療法</strong></p>
<p>Quotient 的尖端體細胞基因組學平台有潛力通過研究患者中存在的自然獲得的遺傳多樣性，解鎖任何疾病的新治療策略。通過三項單獨的協議，Quotient 將利用其體細胞基因組學技術識別導致疾病的藥物靶點，這些靶點有潛力創造 COPD、IPF 和代謝功能障礙相關脂肪肝炎（MASH）的突破性藥物。</p>
<p>根據協議條款，如果 GSK 選擇進一步合作，ProFound 和 Quotient 將通過關鍵的臨牀前活動推進各自的項目，之後 GSK 將擁有將項目推進至臨牀研究的獨佔選擇權。</p>
<p><strong>關於 ProFound™ Therapeutics</strong> ProFound™ Therapeutics 正在發現隱藏在擴展人類蛋白組中的蛋白質，以揭示新藥物和藥物靶點，為多種疾病生產首創藥物。該公司的 ProFoundry™平台利用最先進的蛋白質檢測技術系統地識別和驗證新蛋白，並剖析其治療潛力。其結果是一個不斷擴展的數據庫，包含數以萬計的新蛋白，包括它們的連接性、功能性以及在健康和疾病中的作用。ProFound Therapeutics 成立於 2020 年，由旗艦開創創立。有關更多信息，請訪問 www.profoundtx.com。</p>
<p><strong>關於 Quotient Therapeutics</strong> Quotient Therapeutics 開發突破性藥物，基於患者中存在的自然體細胞遺傳多樣性。通過我們的綜合體細胞基因組學和計算技術，我們獲得了對導致疾病的藥物靶點的無偏見、前所未有的解析，這些靶點被我們用來設計和開發首創療法。通過這一點，我們正在通過廣泛的內部和合作項目管道，開創生物製藥研究和開發的新常態。我們於 2022 年由旗艦開創成立。有關更多信息，請訪問 www.quotient-tx.com。</p>
<p><strong>關於旗艦開創和開創藥物</strong> 旗艦開創發明並建立平台公司，每個公司都有潛力開發多種產品，以改變人類健康、可持續性等。自 2000 年成立以來，旗艦已創辦並培育了 100 多項科學事業，截至 2024 年 7 月的最新融資輪，其管理資產達 140 億美元。目前，旗艦生態系統包括 40 多家公司，包括 Foghorn Therapeutics、Generate Biomedicines、Inari、Indigo Agriculture、Lila Sciences、Moderna、Sana Biotechnology、Tessera Therapeutics 和 Valo Health。</p>
<p>開創藥物是旗艦開創的內部藥物開發單位，致力於構思和開發廣泛的改變患者生活的治療組合，基於旗艦的創新平台。開創藥物利用其團隊的藥物開發專業知識以及旗艦多個科學平台的力量，探索和識別新的產品概念，然後與旗艦的生物平台公司共同推進。在旗艦的創新供應鏈合作伙伴關係中，開創藥物與外部合作伙伴合作，將其獨特的方法應用於合作伙伴的研發優先事項。這些合作伙伴關係是高度共創的戰略聯盟，通過將涵蓋藥物發現、開發和生產全範圍的合作伙伴聚集在一起，加速治療創新。</p>
<p><strong>媒體聯繫人：</strong></p>
<p>旗艦開創</p>
<p>[email protected]</p>
<p>來源 旗艦開創</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIwJk5ld3NJdGVtSWQ9TkUyODkyMiZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjAwNjMwUFJfTkVXU19VU1BSX19fX19ORTI4OTIy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIwJk5ld3NJdGVtSWQ9TkUyODkyMiZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjAwNjMwUFJfTkVXU19VU1BSX19fX19ORTI4OTIy"/></p>

葛蘭素史克

<p>旗艦先鋒公司（Flagship Pioneering）宣佈與 ProFound Therapeutics 和 Quotient Therapeutics 達成新協議，旨在與葛蘭素史克（GSK）合作。這些協議旨在利用 ProFound 和 Quotient 的平台技術發現和驗證針對呼吸系統和肝臟疾病的新療法。如果成功，GSK 可能會將這些項目推進到臨牀研究階段。ProFound 將專注於慢性阻塞性肺病（COPD）和特發性肺纖維化（IPF）的蛋白質檢測，而 Quotient 將使用體細胞基因組學技術針對 COPD、IPF 和 MASH</p>

<p><em>First feasibility agreements under Flagship and GSK framework collaboration</em></p>
<div class="lb-trans"><p><em>旗艦與 GSK 框架合作下的首次可行性協議</em></p>
</div><p><em>Agreements will utilize ProFound's and Quotient's platform technologies to discover and validate novel treatments for respiratory and liver diseases</em></p>
<div class="lb-trans"><p><em>協議將利用 ProFound 和 Quotient 的平台技術來發現和驗證呼吸系統和肝臟疾病的新治療方法</em></p>
</div><p>, /PRNewswire/ -- Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today announced that ProFound Therapeutics and Quotient Therapeutics have entered into separate feasibility agreements with GSK to discover and validate novel targets and therapeutic approaches in respiratory and liver diseases. These are the first company-focused agreements signed under the framework collaboration between Flagship and GSK to combine GSK's disease area expertise and development capabilities with Flagship's ecosystem of bioplatform companies, inclusive of its novel modalities and technologies.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 旗艦開創（Flagship Pioneering）是一家致力於變革性平台和產品的科學創新引擎，今天宣佈 ProFound Therapeutics 和 Quotient Therapeutics 已與 GSK 簽署了單獨的可行性協議，以發現和驗證呼吸系統和肝臟疾病的新靶點和治療方法。這是旗艦與 GSK 框架合作下籤署的首個以公司為中心的協議，旨在將 GSK 的疾病領域專業知識和開發能力與旗艦的生物平台公司生態系統相結合，包括其新穎的模式和技術。</p>
</div><p>&#34;Flagship Pioneering and GSK have a shared mission to accelerate the development of breakthrough medicines for patients with the greatest unmet needs by combining innovative new technologies with deep drug development expertise,&#34; said Paul Biondi, Managing Partner, Flagship Pioneering. &#34;These agreements bring together two pioneering approaches to advance innovative treatments for respiratory and liver diseases, and to identify novel and differentiated targets that may alter the course of disease.&#34;</p>
<div class="lb-trans"><p>&#34;旗艦開創與 GSK 有着共同的使命，通過將創新的新技術與深厚的藥物開發專業知識相結合，加速為最需要幫助的患者開發突破性藥物，&#34;旗艦開創的管理合夥人 Paul Biondi 表示。&#34;這些協議將兩種開創性的方法結合在一起，以推進呼吸系統和肝臟疾病的創新治療，並識別可能改變疾病進程的新穎和差異化的靶點。&#34;</p>
</div><p><strong>Tapping the expanded human proteome to advance novel medicines for respiratory diseases</strong></p>
<div class="lb-trans"><p><strong>利用擴展的人類蛋白組推進呼吸系統疾病的新藥物</strong></p>
</div><p>ProFound will leverage its ProFoundry™ Platform, which combines state-of-the-art protein detection technologies, targeted high-throughput functional validation methods, and advanced computational tools, to unearth a rich source of differentiated potential protein drugs and drug targets from the expanded human proteome, a vast set of previously unrecognized proteins encoded by the human genome. Through two separate agreements, ProFound will advance foundational discoveries to characterize novel proteins with strong genetic associations with Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF) and examine their therapeutic relevance for these diseases.</p>
<div class="lb-trans"><p>ProFound 將利用其 ProFoundry™平台，該平台結合了最先進的蛋白質檢測技術、針對性的高通量功能驗證方法和先進的計算工具，從擴展的人類蛋白組中挖掘出豐富的差異化潛在蛋白藥物和藥物靶點，這是一組由人類基因組編碼的先前未被識別的蛋白質。通過兩項單獨的協議，ProFound 將推進基礎發現，以表徵與慢性阻塞性肺病（COPD）和特發性肺纖維化（IPF）強相關的新蛋白，並檢查它們在這些疾病中的治療相關性。</p>
</div><p><strong>Harnessing somatic genomics to unlock novel therapies for respiratory and liver diseases</strong></p>
<div class="lb-trans"><p><strong>利用體細胞基因組學解鎖呼吸系統和肝臟疾病的新療法</strong></p>
</div><p>Quotient's cutting-edge Somatic Genomics platform has the potential to unlock new therapeutic strategies across any disease by studying the natural, acquired genetic diversity present in patients. Through three separate agreements, Quotient will use its somatic genomics technology to identify disease-causal drug targets that have the potential to create breakthrough medicines for COPD, IPF and Metabolic Dysfunction-Associated Steatohepatitis (MASH).</p>
<div class="lb-trans"><p>Quotient 的尖端體細胞基因組學平台有潛力通過研究患者中存在的自然獲得的遺傳多樣性，解鎖任何疾病的新治療策略。通過三項單獨的協議，Quotient 將利用其體細胞基因組學技術識別導致疾病的藥物靶點，這些靶點有潛力創造 COPD、IPF 和代謝功能障礙相關脂肪肝炎（MASH）的突破性藥物。</p>
</div><p>Under the terms of the agreements, if GSK elects to progress into a further collaboration, ProFound and Quotient will advance their respective programs through key preclinical activities, after which GSK will have the exclusive option to advance the programs into clinical studies.</p>
<div class="lb-trans"><p>根據協議條款，如果 GSK 選擇進一步合作，ProFound 和 Quotient 將通過關鍵的臨牀前活動推進各自的項目，之後 GSK 將擁有將項目推進至臨牀研究的獨佔選擇權。</p>
</div><p><strong>About ProFound™ Therapeutics</strong> ProFound™ Therapeutics is discovering proteins hidden within the expanded human proteome to uncover novel drugs and drug targets, producing first-in-class medicines for a multitude of diseases. The company's ProFoundry™ Platform uses state-of-the-art protein detection technologies to systematically identify and validate novel proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded in 2020 by Flagship Pioneering. For more information, please visit www.profoundtx.com.</p>
<div class="lb-trans"><p><strong>關於 ProFound™ Therapeutics</strong> ProFound™ Therapeutics 正在發現隱藏在擴展人類蛋白組中的蛋白質，以揭示新藥物和藥物靶點，為多種疾病生產首創藥物。該公司的 ProFoundry™平台利用最先進的蛋白質檢測技術系統地識別和驗證新蛋白，並剖析其治療潛力。其結果是一個不斷擴展的數據庫，包含數以萬計的新蛋白，包括它們的連接性、功能性以及在健康和疾病中的作用。ProFound Therapeutics 成立於 2020 年，由旗艦開創創立。有關更多信息，請訪問 www.profoundtx.com。</p>
</div><p><strong>About Quotient Therapeutics</strong> Quotient Therapeutics develops breakthrough medicines informed by natural somatic genetic diversity present in patients. Through our integrated somatic genomics and computational technologies, we gain unbiased, unprecedented resolution into disease-causal drug targets that we leverage to design and develop first-in-class therapies. With this, we are forging a new status quo for biopharma research and development through a broad pipeline of internal and partnered programs. We were founded by Flagship Pioneering in 2022. For more information, visit www.quotient-tx.com.</p>
<div class="lb-trans"><p><strong>關於 Quotient Therapeutics</strong> Quotient Therapeutics 開發突破性藥物，基於患者中存在的自然體細胞遺傳多樣性。通過我們的綜合體細胞基因組學和計算技術，我們獲得了對導致疾病的藥物靶點的無偏見、前所未有的解析，這些靶點被我們用來設計和開發首創療法。通過這一點，我們正在通過廣泛的內部和合作項目管道，開創生物製藥研究和開發的新常態。我們於 2022 年由旗艦開創成立。有關更多信息，請訪問 www.quotient-tx.com。</p>
</div><p><strong>About Flagship Pioneering and Pioneering Medicines</strong> Flagship Pioneering invents and builds platform companies, each with the potential for multiple products that transform human health, sustainability and beyond. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, operating with $14 billion of assets under its direction as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises more than 40 companies, including Foghorn Therapeutics, Generate Biomedicines, Inari, Indigo Agriculture, Lila Sciences, Moderna, Sana Biotechnology, Tessera Therapeutics and Valo Health.</p>
<div class="lb-trans"><p><strong>關於旗艦開創和開創藥物</strong> 旗艦開創發明並建立平台公司，每個公司都有潛力開發多種產品，以改變人類健康、可持續性等。自 2000 年成立以來，旗艦已創辦並培育了 100 多項科學事業，截至 2024 年 7 月的最新融資輪，其管理資產達 140 億美元。目前，旗艦生態系統包括 40 多家公司，包括 Foghorn Therapeutics、Generate Biomedicines、Inari、Indigo Agriculture、Lila Sciences、Moderna、Sana Biotechnology、Tessera Therapeutics 和 Valo Health。</p>
</div><p>Pioneering Medicines, Flagship Pioneering's in house drug development unit, is dedicated to conceiving and developing a broad portfolio of life-changing treatments for patients built from Flagship's innovative platforms. Harnessing the drug development expertise of its team together with the power of Flagship's multiple scientific platforms, Pioneering Medicines explores and identifies new product concepts which are then advanced jointly with Flagship's bioplatform companies. Within Flagship's Innovation Supply Chain partnerships, Pioneering Medicines works with external collaborators to apply its unique approach to partners' R&amp;D priorities. These partnerships are highly co-creative strategic alliances that accelerate therapeutic innovation by bringing together partners spanning the full spectrum of drug discovery, development, and production.</p>
<div class="lb-trans"><p>開創藥物是旗艦開創的內部藥物開發單位，致力於構思和開發廣泛的改變患者生活的治療組合，基於旗艦的創新平台。開創藥物利用其團隊的藥物開發專業知識以及旗艦多個科學平台的力量，探索和識別新的產品概念，然後與旗艦的生物平台公司共同推進。在旗艦的創新供應鏈合作伙伴關係中，開創藥物與外部合作伙伴合作，將其獨特的方法應用於合作伙伴的研發優先事項。這些合作伙伴關係是高度共創的戰略聯盟，通過將涵蓋藥物發現、開發和生產全範圍的合作伙伴聚集在一起，加速治療創新。</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒體聯繫人：</strong></p>
</div><p>Flagship Pioneering</p>
<div class="lb-trans"><p>旗艦開創</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE Flagship Pioneering</p>
<div class="lb-trans"><p>來源 旗艦開創</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIwJk5ld3NJdGVtSWQ9TkUyODkyMiZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjAwNjMwUFJfTkVXU19VU1BSX19fX19ORTI4OTIy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NE28922&amp;Transmission_Id=202511200630PR_NEWS_USPR_____NE28922&amp;DateId=20251120"/></p>

06:30 ET
			
			
				Flagship Pioneering Announces New Agreements with ProFound Therapeutics and Quotient Therapeutics Under its Collaboration with GSK

旗艦開創公司宣佈在與 GSK 的合作框架下，與 ProFound Therapeutics 和 Quotient Therapeutics 達成新協議